Bacci G, Picci P, Mercuri M, Bertoni F, Ferrari S
Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy.
Clin Orthop Relat Res. 1998 Jan(346):178-89.
Between March 1983 and December 1994, 65 patients with malignant fibrous histiocytoma of bone in the extremities were treated with neoadjuvant chemotherapy administered according to four different regimens. A limb salvage was done in 58 patients (89%) and amputation in seven. The histologic response to preoperative chemotherapy was good (90% or more tumor necrosis) in 16 patients (25%) and poor in 49 (75%). At a median followup of 7 years (range, 2-13 years), 40 patients (69%) remained continuously free of disease and 20 patients experienced relapse (18 with metastases and two with local recurrences followed by metastases). The rate of disease free survival was significantly higher for patients who had a good response than for those who had a poor response (94% versus 61%), although no significant differences in histologic response and disease free survival were seen with the four different regimens. These results show that a high percentage of patients with malignant fibrous histiocytoma of the extremities can be cured with neoadjuvant chemotherapy and that for most of them it is possible to avoid amputation.
1983年3月至1994年12月期间,65例四肢骨恶性纤维组织细胞瘤患者接受了新辅助化疗,化疗方案分为四种。58例患者(89%)接受了保肢手术,7例接受了截肢手术。术前化疗的组织学反应良好(肿瘤坏死率达90%或更高)的患者有16例(25%),反应较差的有49例(75%)。中位随访时间为7年(范围2至13年),40例患者(69%)持续无病生存,20例患者出现复发(18例发生转移,2例局部复发后发生转移)。反应良好的患者无病生存率显著高于反应较差的患者(94%对61%),尽管四种不同化疗方案在组织学反应和无病生存率方面未见显著差异。这些结果表明,大部分四肢骨恶性纤维组织细胞瘤患者可通过新辅助化疗治愈,且多数患者可避免截肢。